Vnitr Lek 2021, 67(5):310-314 | DOI: 10.36290/vnl.2021.079

Carcinoid syndroma - diagnosis and management

Soňa Kiňová, Michal Koreň

I. interná klinika LF UK a UN Bratislava

Neuroendocrine tumors (NETs, originally termed "carcinoids") create a relatively rare group of neoplasms with an approximate incidence rate of 5 to 8 cases per 10 000 persons. NETs predominantly demonstrate indolent disease biology for many years. They become symptomatic when they are large enough or when they metastasize to the liver or the lungs, bones, or other sites. Roughly 30% to 40% of subjects with NETs develop carcinoid syndrome. Signs and symptoms of carcinoid syndrome are bronchospasm, flushing, diarrhea and cramping, cyanosis and pellagra. White plaque-like deposits on the endocardial surface of heart structures are characteristic for carcinoid heart disease. The treatment of patients with carcinoid syndrome is multi-faceted due to the necessity to manage simultaneously the systemic cancer disease as well as the signs of carcinoid syndrome and includes resection or debulking of tumor mass, biological treatment with somatostatin analogues and peptide receptor radionuclide treatment.

Keywords: neuroendocrine tumors, carcinoid syndroma, somatostatin analogues, peptide receptor radionuclide treatment, biological treatment.

Published: August 25, 2021  Show citation